Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the long-term tolerability and safety of
natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's
Disease who have previously participated in studies CD251, CD301, CD303, CD306, or CD307.